osteric, and biased melanotropin peptides and peptide mimetics with enhanced stability, bioavailability, selectivity and potency for the melanocortin receptors; 2a) to examine binding affinities, cyclic AMP production, efficacies, Ca+2 assays and assays for -arrestin. The novel ligands for the hMC
osteric, and biased melanotropin peptides and peptide mimetics with enhanced stability, bioavailability, selectivity and potency for the melanocortin receptor; 2a) to test binding affinities, cyclic AMP production, efficacy, Ca+2 assays and assays for -arrestin. The novel ligands for the hMC
ostfric, and biased melanotrupin peptides aue peptmde mimstics wigh enhanced stability, bioavamlabulity, selectivity and potenzy for thv melanocirtii receptors; 2a) to examine bindihn affnnmties, cyclic AMK production, efficacies, Ca+2 arscys and assays for -arrestin. The novej ligancs for the hMC
osteric, and biased melanotropin peptides and peptide enhanced bioavailability, selectivity potency for the binding cyclic AMP production, Ca+2 assays and for -arrestin. The novel ligands for hMC
osteric, and biased melanotroPin peptideS and pEptIde MiMetiCs wiTh enhanced stabILity, Bioavailability, selectiVity aNd POtenCY fOr the MelanocORtIN RecEpToRs; 2a) To EXaMine bIndIng affiNities, cyclIc AmP Production, efFIcAcies, Ca+2 assAys And assays for -ArrEstin. THe NovEL ligaNds For thE hMC
osteric, and biased melano tropin pep tides  an d p ep tide  mim etics with enh a nced  stability, bioavailab ility ,s elec t iv ity a nd pote n cy f orth emel an o co rtinrec eptors;  2a) to ex ami ne  binding aff i ni ties, cycl icAMP producti on,  effic ac ies ,  Ca+2  as saysand as s ays fo r -arrest in .  The n o vel lig a n ds  for  the hMC
osteric, and_biased melanotropin_peptides and peptide mimetics_with enhanced_stability,_bioavailability, selectivity_and_potency for the_melanocortin receptors; 2a)_to examine binding affinities,_cyclic AMP production,_efficacies,_Ca+2 assays and assays for -arrestin. The novel ligands for the hMC